A Novel Approach to Antigen-Specific Deletion of CTL with Minimal Cellular Activation Using α3 Domain Mutants of MHC Class I/Peptide Complex  by Xu, Xiao-Ning et al.
Immunity, Vol. 14, 591–602, May, 2001, Copyright ª 2001 by Cell Press
A Novel Approach to Antigen-Specific Deletion
of CTL with Minimal Cellular Activation Using a3
Domain Mutants of MHC Class I/Peptide Complex
express Fas, to the risk of self-induced death. Activa-
tion-induced cell death (AICD) is an important immuno-
logical control mechanism for peripheral tolerance and
can occur shortly after activation, where it is mainly
triggered by Fas/FasL interactions (Lenardo et al., 1999).
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3 Division of Infectious Disease and Immunology spectively. Although effective in many cases, conven-
tional therapy relies upon broad spectrum immunosup-Queensland Institute of Medical Research
Brisbane 4029 pression, with the consequent risk of opportunistic
infection or tumorogenesis. One obvious route for tar-Australia
geted immunotherapy is the systemic administration of
agonist peptide to induce apoptosis of reactive lympho-
cytes. This approach has two major limitations. First, inSummary
many cases the responsible peptide epitopes have not
yet been identified. Second, although such therapy hasIn this study, we have compared the effector functions
and fate of a number of human CTL clones in vitro or ex been shown to work in animal models, the activation,
proliferation, and cytokine release which is induced asvivo following contact with variant peptides presented
either on the cell surface or in a soluble multimeric a consequence of activation can lead to damage of the
lymphoid organs and to general immunosuppressionformat. In the presence of CD8 coreceptor binding,
there is a good correlation between TCR signaling, (Aichele et al., 1997).
The aim of this study was to evaluate and develop akilling of the targets, and FasL-mediated CTL apo-
ptosis. Blocking CD8 binding using a3 domain mutants novel approach to selectively delete antigen-specific
CTL, with minimal cellular activation. We tested a num-of MHC class I results in much reduced signaling and
reduced killing of the targets. Surprisingly, however, ber of human CTL clones in vitro or ex vivo stimulated
by MHC/peptide presented either by cells or as solubleFasL expression is induced to a similar degree on
these CTLs, and apoptosis of CTL is unaffected. The multimeric complexes. The studies have revealed an
interesting difference in the activation threshold for CTLability to divorce these events may allow the deletion
of antigen-specific and pathological CTL populations killing of targets versus CTL apoptosis in the presence
or absence of CD8/MHC interaction.without the deleterious effects induced by full CTL
activation.
Results
Introduction
Correlation of Death of the CTLs and the Targets
The engagement of TCR with peptide/MHC complexes To investigate the balance between the killing activity
is a critical event in the initiation of the T cell response. and the death of CTLs, we performed CTL assays in
Binding of the coreceptors CD4 or CD8 to the MHC which both the death of the CTLs and the death of
plays an important role in the augmentation of TCR- their targets were measured. HIV-1 gag-specific and A2-
triggered activation of most T cells. Signaling via the restricted CTL clone was incubated with A21 B cells
TCR can have a number of outcomes, ranging from pulsed (and subsequently washed) with index peptide
activation/proliferation through anergy to apoptosis at an effector:target (E:T) ratio of 2:1. After a 12 hr incu-
(Monks et al., 1998; Van Parijs and Abbas, 1998). bation, the apoptosis of CTLs and targets was measured
After TCR engagement, CTLs kill target cells by two by tristaining with anti-CD8-Tricolor, anti-CD19-PE, and
major pathways. Perforin-dependent cytotoxicity in- Annexin V-FITC. Using the gag index peptide, we saw
volves the exocytosis of preformed CTL granules con- up to 27% specific killing of targets and 35% death of
taining perforin and various granzymes, which synergize the CTLs. A representative experiment is shown in Fig-
to induce death of the target cells. Activated CTLs also ure 1A; interestingly, following stimulation with index
express Fas ligand (FasL), which can engage Fas on peptide, the CTLs distribute between CD8high and CD8low
the target cells and trigger apoptosis through a well- populations, and most of the apoptotic cells (80%) re-
characterized pathway. Upregulation of FasL on CTL side in this latter population. Next, we used a range of
is a two-edged sword, as it also exposes CTL, which naturally observed variant gag peptides. The variants
have comparable binding affinities for MHC A2 but differ
in their abilities to activate CTL (Sewell et al., 1997).4Correspondence: xiaoning@molbiol.ox.ac.uk
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Figure 1. Detection of Apoptosis of CTLs and Target Cells
(A) HIV-1 gag-specific A2-restricted CTLs were cocultured with an autologous BCL prepulsed with either gag index peptide (SLYNTVATL) or
control peptide (HIV-1 pol). Cells were stained with anti-CD19-PE, anti-CD8-Tricolor, and Annexin V-FITC. Apoptosis of CTLs or targets was
assessed by gating CD81 and CD191 populations, respectively.
(B and C) Gag-specific CTLs were cocultured with the BCLs prepulsed with (B) HIV-1 gag variant peptides as indicated or (C) with different
doses of index peptide. Apoptosis of both CTLs and target was determined after a 12 hr incubation as above.
(D) Influenza matrix-specific A2-restricted CTLs (Flu-CTL) were cocultured with T2 cells stably transfected with the b2M/FluMP58-66 matrix
fusion construct at different E:T ratios. CTL death was assessed by Annexin V staining, and death of targets was assessed by a 4 hr 51Cr
release assay.
There was a good correlation between target cell and One explanation for the above results was that CTLs
were killing each other in a peptide-specific fashion byCTL death for these variants, with both the index and
3F sensitizing both target and CTL to death, while vari- binding residual peptide left in solution (even though
targets were extensively washed and supernatant fromants 3S and 3H had no effect on either (Figure 1B).
Interestingly, 3F5A, an antagonist for the index (Sewell a CTL assay did not cause death when transferred onto
fresh CTL; data not shown). To exclude formally thiset al., 1997), had no effect on CTL death. Titration of
the index peptide showed similar effects on CTL and possibility, we developed a system free of added pep-
tide. A Flu matrix peptide was covalently linked to b2Mtarget cell death (Figure 1C).
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by cloning the corresponding DNA sequences onto its studies on CD41 T cells, Fas-FasL interaction plays a
central role in the death of these human CTL clonesN terminus. T2, an A2 cell line deficient in the TAP genes
and lacking cell surface expression of MHC class I, was because Fas-Fc or anti-FasL mAb inhibited up to 80%
of CTL death.stably transfected with the b2M fusion. The transfected
cells were then used as targets in a Flu-specific CTL
assay (Figure 1D). The results again demonstrated con- CD8 Is Not Required to Signal CTL Death
siderable death of CTL, confirming our original observa- In a further search for molecules regulating the balance
tions with the Gag clone. In addition, we performed the between target and CTL death, we examined the role
assay at E:T ratios from 0.1–10:1. Decreasing the E:T of the coreceptor CD8. Most human CTLs kill their tar-
ratio dramatically increased the apoptosis of the CTLs gets in a CD8-dependent fashion (i.e., blocking CD8
(presumably by maximizing their exposure to antigen), blocks/reduces CTL killing). Anti-CD8 was added to a
whereas increasing the ratio lead to better CTL survival CTL assay using, as targets, the A2-positive B cell line
and a concomitant increase in the efficiency of target JY transfected with the FluMP58-66/b2M fusion construct.
cell killing. Interestingly, the two lines cross at an E:T These assays confirmed that blocking CD8/MHC inter-
ratio close to 1:1, suggesting that in these assays, on action, over a range of E:T ratios, reduced the killing of
average, one CTL only killed a single target. This is in targets by up to 80%. Interestingly, over the same time
agreement with previous studies that show that AICD period, there was little effect on the death of CTL (Fig-
mediated by FasL/Fas can occur in a cell-autonomous ure 4A).
fashion, presumably due to folding of the cell membrane, Anti-CD8 antibodies have been shown to either block
allowing FasL to engage Fas on the same cell (Bonfoco or augment TCR-MHC/peptide interactions, depending
et al., 1998; Brunner et al., 1995; Dhein et al., 1995). on binding to different epitopes on CD8 (Daniels and
Jameson, 2000). To further characterize this effect, mu-
tants of MHC class I (A2 and B4402) were constructed.CTL Death Can Be Induced by Peptide/MHC
Multimeric Complexes Based on the CD8-HLA-A2 structure (Gao et al., 1997),
two amino acid substitutions (aa 227/228, from DT toPeptide/MHC tetramers enhance the avidity of TCR
binding and have been used extensively as staining re- KA) were made in the a3 domain, which were predicted
to abolish the interaction. As expected, this mutationagents to analyze specific T cell populations and also
to study T cell activation (Boniface et al., 1998). We took abrogates binding to CD8 measured using Biacore anal-
ysis (M.A.P. et al., unpublished data). Wild-type and mu-advantage of this technology to produce a target cell-
free system to assess the contribution of adhesion/ac- tant A2 molecules were stably expressed in .221 cells,
which lack MHC class I, and comparable levels of ex-cessory molecules to the death of CTL. We constructed
multimers using the A2 heavy chain complexed with pression were verified by FACS analysis (data not
shown). When pulsed with the Flu peptide, the killing ofthe b2M/FluMP58-66 fusion protein as described above.
These multimers efficiently triggered death of Flu-spe- targets expressing mutant A2 was reduced to a similar
degree as blocking with anti-CD8 mAb. Remarkably, incific (MP58-66) CTL (Figure 2A). Death of CTL induced by
magnetic beads saturated with the multimers (Figure 2B) spite of the lack of interaction with CD8, the A2 mutant-
expressing cells were still competent to induce deathshowed a similar dose response curve to that obtained
using the T2 targets described above (Figure 1D). It has of Flu-specific CTL (Figure 4B). Next, we tested whether
this system could apply to alloreative CTL in which thepreviously been shown that reducing the stoichiometry
of the MHC:streptavidin reduced T cell activation/signal- endogenous antigenic peptide remains unknown. We
studied the well-characterized Epstein-Barr Virus-spe-ing (Savage et al., 1999). We increased the loading of
beads with agonist monomer to 0%, 25%, 50%, and cific HLA B8-restricted CTL clone (LC13), which cross-
recognizes HLA B4402 (Burrows et al., 1999). Cells ex-75% of maximum by varying the ratio of two A2 com-
plexes containing either index (FluMP58-66) peptide or an pressing B4402 wild-type or the B4402 mutant lacking
CD8 binding were equally competent at causing AICDirrelevant peptide. Increasing the loading of FluMP58-66
MHC from 25% to 100% increased the death of CTL of the alloreactive CTL; however, killing of targets ex-
pressing the mutant B4402 was greatly reduced (Fig-(Figure 2C).
A number of cytokines and costimulatory molecules ure 4C).
.221 cells express Fas and are very sensitive to killinghave been suggested to play a role in the modulation
of AICD. To look for possible modulators, we took two by FasL (data not shown), so we reasoned that stimula-
tion of T cells with mutant MHC lacking the ability toapproaches. First, CTLs were incubated with multimer
beads in the presence of either IL-2 or anti-CD28. Anti- interact with CD8 may abolish perforin-dependent cyto-
toxicity but that some residual killing activity may beCD28 was without effect, while IL-2 in some cases led
to a small increase in CTL death. In addition, to provide mediated by FasL. CTL assays with targets expressing
mutant A2 or B4402 were repeated in the presence ofa source of costimulatory interactions, we added irrele-
vant APCs to the culture. Neither autologous nor alloge- soluble Fas or neutralizing anti-FasL mAb. These two
blocking reagents inhibited the residual CTL activity toneic APCs reduced the death of CTL (Figure 3A).
To examine the mechanism of CTL death, we included background levels, indicating that only FasL killing is
activated in CTL stimulated without CD8 coreceptor en-caspase inhibitors in the CTL assay. z-VAD blocked the
tetramer-induced apoptosis of CTL, implying a caspase- gagement (Figure 4D).
To further confirm the results of cells expressing MHCdependent apoptotic pathway (Figure 3B). Next, we in-
cubated cells with soluble Ig-Fc chimeras to block the class I mutant, we also tested the activity of the a3
domain mutation of A2 in the target-free assay systemdeath induced by FasL, TNF, or TRAIL. Consistent with
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Figure 2. Induction of Apoptosis by Multi-
meric MHC Class I Complexes
(A) Flu-CTLs were cultured for 12 hr with
beads (five beads per cell) coated with
FluMP58-66-A2wt or control irrelevant (Irrel-
A2wt) tetramers, and death of CTLs was as-
sessed by Annexin V staining. The Flu-A2wt
multimers did not induce apoptosis of mela-
noma-specific CTLs (data not shown).
(B) Dose-dependent (from zero to ten beads
per cell) induction of the Flu-CTL apoptosis
by the Flu-A2wt multimer beads assessed by
Annexin V staining.
(C) Density-dependent induction of CTL apo-
ptosis. Mixed multimers were formed by load-
ing streptavidin-coated beads with different
molar ratios of two A2 monomers (Flu-A2
wild-type and Irrel-A2 wild-type). These
“mixed multimers” were then assessed for
the induction of CTL apoptosis as above.
by constructing MHC complexes containing mutant A2 of experiments, we loaded beads with a mixture of wild-
type/irrelevant or wild-type/mutant A2 complexes andcomplexed to the b2M-Flu fusion protein (similar to the
A2wt-b2M/FluMP58-66 tetramer described above). The measured z phosphorylation by Western blot and also
measured death of the CTL by Annexin V staining. Whenmutant tetramer was still able to stain the FluMP58-66 CTL
clone, although to a reduced intensity (Figures 5A and the wild-type complexes are sequentially replaced by
irrelevant complexes, there is a good correlation be-5B). This reduction likely reflected a reduced binding
avidity, as it was similar to that seen if a blocking anti- tween CTL apoptosis and the level of T cell activation
as evidenced by z chain phosphorylation (Figure 6B,CD8 mAb was applied before the tetramer staining (data
not shown). In spite of the weaker binding, beads loaded lanes 1–5). However, as the wild-type complexes are
replaced by the a3 domain mutant A2 complexes, thewith the mutant A2 complexes were still fully competent
to induce death of CTL (Figure 5A), and this showed a level of apoptosis remains constant, while tyrosine
phosphorylation is much reduced (Figure 6B, lanes 1similar dose response to beads loaded with wild-type
complexes (Figure 5C). and 6–9)
Thus, z phosphorylation and CTL death appear to
have been dissociated by blocking interaction with CD8.Apoptosis of CTL Induced by the MHC Class I Mutant
Is Independent of TCRz Chain Phosphorylation The reduced signaling/activation induced by the mutant
multimers was also evidenced by a reduced expressionThe induction of AICD in the absence of CD8 interaction
was surprising, as blocking CD8 has been shown to of the early activation marker CD69 when compared
with CTL stimulated with the wild-type multimers (datainhibit TCR signaling as determined by phosphorylation
of TCRz or Zap70 (Kersh et al., 1998). CTLs were ex- not shown).
posed to beads coated with wild-type and mutant A2-
Flu complexes, and tyrosine phosphorylation was mea- Death of CTL in Response to Antigen Is Also Found
to Be CD8 Independent in Polyclonal CTL Responsessured by Western blotting. Compared to control, mutant
A2 triggered little z chain phosphorylation, while wild- The experiments detailed above examined apoptosis of
CTL clones maintained in long-term culture. To confirmtype beads triggered considerable phosphorylation over
the indicated time course (Figure 6A). In a further series that these results were applicable to polyclonal CTL
Deletion of CTL by the Mutant MHC Class I
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Figure 3. Mediators of CTL Death
(A) Flu-CTLs were cultured for 12 hr with Flu-
A2wt multimeric beads in the presence of ei-
ther IL-2 (20 U/ml), anti-CD28 (1 mg/ml), or
autologous/allogeneic B cells. The apoptosis
of CTLs was then determined by JAM assay
([3H]thymidine incorporation), as described in
Experimental Procedures.
(B) Inhibition of CTL apoptosis (assessed by
Annexin V or TUNEL), using caspase inhibi-
tors or soluble Ig-Fc chimeras of the indicated
death receptors.
responses in vivo, we examined an HLA-A2-restricted provided by the feeder cells can inhibit AICD of effector
CTLs or some of memory CTLs, which are resistant toanti-cytomegalovirus (CMV) response from a healthy in-
dividual. Fresh isolated peripheral blood mononuclear Fas-mediated apoptosis and can be expanded in vitro.
cells (PBMC) were cocultured with peptide-pulsed tar-
gets in the presence or absence of blocking anti-CD8 Discussion
mAb, in experiments analogous to those depicted in
Figure 4A. CD81 CTLs need to exercise potent cytotoxicity to elimi-
nate foreign pathogens, but, at the same time, they needThe A2 CMV-specific CTL population was assessed
by staining with a CMV-A2 tetramer. As expected, gating to maintain unresponsiveness against self-antigens.
Self-tolerance is achieved by both thymic and postthy-on this population revealed that stimulation of cells with
CMV peptide-pulsed targets (subsequently washed sev- mic (peripheral) processes. Because thymic tolerance
is incomplete, some potentially autoreactive T cells willeral times) for 6 hr in the absence of CD8 led to significant
CTL death when compared with targets pulsed with escape to the periphery, where tolerance can be
achieved by several mechanisms, including the induc-irrelevant peptide (Figure 7A). Across a range of E:T
ratios, in the presence of the blocking anti-CD8 mAb at tion of anergy or AICD upon exposure to their specific
antigen. However, in some cases, this may be incom-the same or double the concentration used to block the
CTL clones, CTL death was not blocked, confirming plete, and the combination of genetic predisposition,
injury, or exposure to crossreactive antigens may acti-our results using the FluMP58-66-A2-specific CTL clones
(Figure 7B). vate these cells and cause autoimmunity. Current ther-
apy for these conditions often relies upon broad spec-It is noteworthy that some polyclonal CTL can be
expanded in vitro with the agnostic peptides in the pres- trum immunosuppression, with the consequent risk of
opportunistic infection or malignancy. It would clearly beence of high numbers of allogeneic “feeder” cells (.50-
fold). This indicates that additional costimulatory signals desirable to manipulate the immune system to eliminate
Immunity
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Figure 4. The Role of CD8 in CTL Function and Apoptosis
(A) The effect of anti-CD8 antibody on the death of CTLs and targets. Flu-CTLs were cocultured with untransfected JY cells (A21 B cell line)
or JY transfected with the Flu-b2M fusion construct (JY/Flu). Cells were incubated in the presence or absence of a blocking anti-CD8 mAb
(MF8 1/1000 dilution of ascites) at different CTL:target ratios. After an 8 hr culture, the percentage of apoptosis of CTLs was determined by
Annexin V staining of T cells gated using anti-CD3. In parallel, the death of target cells was determined at the same time point by a 51Cr
release.
(B and C) The effect of MHC class I a3 mutants on the death of CTLs and targets. Flu-CTLs were cocultured with A2 wild-type (A2wt)- or A2
mutant (A2mt)-expressing .221 cells pulsed with or without FluMP58-66 peptide (subsequently washed) at different CTL:target ratios. Similarly,
the B4402 alloreactive CTLs (LC13) were cocultured with either B4402wt- or B4402mt-expressing cells, and the death of CTLs and targets
was determined as described above.
(D) Residual cytotoxicity induced by the MHC class I a3 mutants is mediated by FasL. Soluble Fas-Fc fusion proteins (20 mg/ml) or anti-FasL
neutralizing mAb (5 mg/ml) were added to the culture, as described in (B) and (C).
Deletion of CTL by the Mutant MHC Class I
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Figure 5. Induction of Apoptosis of CTLs by Multimeric MHC Class I a3 Mutant Complexes
(A) Tetramer staining and death induction by mutant Flu-A2 multimeric beads, which do not bind CD8. Flu-CTLs were stained with control,
wild-type, or a3 mutant tetramers (5 mg/ml; 30 min at 378C followed by staining with anti-CD8-Tricolor) (left panel). Apoptosis of CTLs was
assessed by Annexin V staining, following a 12 hr incubation with control, wild-type, or mutant multimeric beads (five beads per cell) (right
panel). (B) Dose-dependent binding to tetramers to CTL. (C) Induction of apoptosis of CTLs by the mutant multimers. Experiments were
performed as described in Figures 2A and 2B.
only the disease-specific T cells. To achieve T cell toler- shown to work only in murine models, where they can
prevent diseases such as experimental autoimmune en-ance as a therapeutic goal, it is essential to identify the
self-antigens recognized by the T cells and to define cephalomyelitis, a CD41 T cell-driven disease (Gaur et
al., 1992), or virus-induced autoimmune diabetes medi-the means for specifically targeting disease-triggering
T cells. Peptide-based immunotherapies have been ated by CD81 CTLs (Aichele et al., 1996). However, T
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Figure 6. Signaling and Apoptosis Induced
by Wild-Type and Mutant MHC Complexes
(A) Phosphorylation of the TCRz chain in-
duced by wild-type or mutant MHC com-
plexes. Flu-CTLs were cultured with beads
coated with A2 monomers for up to 30 min.
z chain phosphorylation was detected by
Western blotting with an anti-phosphotyro-
sine mAb. (B) Comparison of CTL death with
z chain phosphorylation. Beads were coated
with the indicated molar ratios of wild-type
versus irrelevant (lanes 1–5: 4:0, 3:1, 2:2, 1:3,
0:4 [1], respectively) or versus mutant (lanes
6–9: 3:1, 2:2, 1:3, 0:4 [1], respectively) A2
complexes. CTLs were incubated with the
beads for 5 min for z phosphorylation analysis
as described above, and the apoptosis of
CTLs was measured by Annexin V staining,
following another 12 hr incubation. As a con-
trol for protein loading, Western blots were
stripped and reprobed with an antibody to (A)
b-actin or total ZAP-70 (B).
cell deletion induced by the agonist peptide can result (Luescher et al., 1995). Consistent with this, we observed
that blocking of CD8 substantially reduced phosphoryla-in severe immunopathological damage in both CD4- and
CD8-driven murine models in vivo, such that its thera- tion of the TCRz chain, which characterizes the classical
TCR signaling pathway in T cell activation and perforin-peutic utility is limited.
In this study, we reveal a novel approach to delete mediated killing of target cells. On the other hand,
blocking of CD8 rendered T cells which were still fullyantigen-specific CTL with minimal cellular activation by
disrupting CD8 contact with the a3 domain mutants competent to upregulate FasL and undergo AICD. Inhibi-
tion of CD8-associated p56lck by herbimycin A has alsoof the MHC class I/peptide complex (Figure 7C). This
approach is particularly useful for elimination of autore- been shown to have little effect on FasL-mediated cyto-
toxicity (Latinis and Koretzky, 1996). Selective inductionactive or alloreactive CTL, for which, in most human
cases, the antigenic peptides remain unidentified. In of FasL-mediated apoptosis without complete TCRz
chain phosphorylation by altered peptides has been re-addition, our data provide insights into the biological
role of CD8/MHC class I interaction in regulation of the ported in murine CD41 T cells (Combadiere et al., 1998).
Thus, it appears that very limited TCR signaling canfunction and fate of CTL.
CD8 binding to MHC class I brings the intracellular trigger surface expression of FasL, conceivably by
translocation of preformed, intracellular FasL to the celldomain into close proximity with the tyrosine kinase
p56lck and other components of the TCR signaling com- surface, as previously described in other cell types
(Kiener et al., 1997; Lowin et al., 1996).plex. Blocking this interaction therefore reduces the
avidity of TCR-ligand binding and prevents coreceptor- The CD8-independent death of CTL has several impli-
cations. First, surface expression of CD8 could regulateassociated p56lck from joining the TCR/CD3 complex
Deletion of CTL by the Mutant MHC Class I
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Figure 7. Study of Polyclonal CMV-Specific CTL Response
(A) PBMC from a normal CMV1 HLA-A21 individual were incubated for 6 hr with B cells pulsed with irrelevant or CMV matrix peptide
(NLVPMVATV). CMV-A2-specific CTLs in this mix of PBMC were identified using a CMV-A2 tetramer (see Experimental Procedures). Apoptosis
of the tetramer-positive cells was determined by counterstaining with Annexin V-FITC and anti-CD3-Tricolor.
(B) The effect of blocking CD8 on CMV-specific CTL death. Cells were cultured as above at varying E:T ratios (PBMC:B cells) in the presence
or absence of blocking anti-CD8 mAb. Apoptosis of CMV-A2 cells was assessed by Annexin V staining of the CD3/tetramer-gated cells shown
in (A).
(C) The role of CD8 in regulation of CTL and target cell death. Full activation induced by TCR and CD8 engagement leads to granule release
and the expression of FasL on CTL (left panel), whereas a3 domain mutants of MHC class I abolish CD8 coreceptor engagement and lead
to a reduced TCR signal that upregulates FasL expression but does not lead to perforin release (right panel).
Immunity
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transfected into .221 cells by electroporation and subsequently cul-target cell and CTL death. Indeed, downregulation of
tured in the presence of selection antibiotic neomycin (G418;CD8 has been demonstrated to occur on stimulation of
GIBCO). The GFP-positive cells were then sorted and stained withsome but not all CTL clones (Robbins and McMichael,
anti-class I mAb (W6/32) to confirm equal cell surface expression.
1991). Our results suggest that this will reduce target
cell killing without affecting CTL apoptosis; thus, down-
Peptides and Tetramersregulation of CD8 may provide a potent mechanism to
The HLA-A2-restricted natural variant peptides from HIV-1 gag
generate peripheral tolerance. Further analysis of the p17-8, 3F (SLFNTVATL), 3S (SLSNTVATL), 3H (SLHNTVATL), and
CTL assay presented in Figure 1A shows that following 3F5A (SLFNAVATL) (Sewell et al., 1997) were used to pulse autolo-
antigen contact CTL, which are initially CD8high, separate gous B cells at 5 mM or as indicated for 2 hr. BCLs were then washed
at least three times and resuspended for use as targets. Productioninto two populations: CD8high and CD8low. Most of the
of MHC-peptide tetrameric complexes has been described (Altmanapoptotic cells (80%) were CD8low. We propose that the
et al., 1996). In brief, purified HLA-A2 heavy chain and b2M/peptideinitial contact of CTL with targets leads to full T cell
fusion proteins were produced in Escherichia coli BL21 DE3 pLysS
activation, killing of the target, and downregulation of using pET expression vectors. The BirA biotinylation site was added
CD8. At this stage, the reduction of CD8 expression to the C terminus of A2. The A2 heavy chain and b2M/peptide fusion
may limit target cell killing while leaving CTL apoptosis were refolded using standard buffers. The 45 kDa refolded product
was isolated by FPLC and biotinylated with BirA. For cell surfaceunaffected. This, combined with the downregulation of
staining, tetramers were prepared by mixing monomers with strep-the T cell receptor, will limit the ability of CTL to engage
tavidin-phycoerythrin (PE) conjugate (Sigma *E-4011) at a molarand kill multiple targets and may form the basis of immu-
ratio of 4:1. For cell culture, we used magnetic multimeric beads
nological exhaustion. Support for this hypothesis comes prepared by mixing an excess of monomers with beads coated
from a recent report showing that inhibition of CD8 gene avidin (7 3 105 molecules/bead; Dynabeads M-280). To reduce the
expression by methylation led to the death of misse- proportion of A2 wild-type MHC complexes, we mixed beads with
optimal amounts of FluMP58-66 A2 monomers and irrelevant (mela-lected peripheral CD8 T cells in vivo via a Fas/FasL
noma) A2 monomers at molar ratio of 3:1, 2:2, and 1:3, respectively.pathway (Pestano et al., 1999).
All beads were washed three times with culture medium to removeIn summary, our findings may provide a mechanism
sodium azide before the assays.
for the deletion of specific CTL populations, without the
concomitant T cell activation and end organ damage
Tetramer Stainingthat can be induced by full stimulation with agonist pep-
For tetramer staining, cells were incubated at 378C for 15 to 30
tide (Combadiere et al., 1998). Peptide/MHC complexes min to allow TCR-mediated binding and rapid internalization of the
created with mutant heavy chain lacking CD8 interac- tetramer (Whelan et al., 1999). After washing, cells were counter-
tion would not lead to this detrimental T cell activation stained with additional antibodies, such as anti-CD8-Tricolor
(*MHCD0806; Caltag) or anti-CD3-Tricolor (*MHCD0306; Caltag). Asand may allow antigen-specific deletion of the disease-
this step is done following binding and internalization of tetramer,mediating CTL. The other advantage of this approach
the possibility that anti-CD8 or anti-CD3 may block tetramer bindingis that it can allow deletion of CTL without the need to
is avoided.
identify the antigenic peptide. So, for instance, in these For the analysis of the CMV-A2-specific polyclonal CTL, freshly
experiments we were able to induce apoptosis of B4402- purified PBMC were prestained with the CMV-A2 wild-type tetra-
allospecific CTL by expressing an a3 domain mutant in mers for 15 min at 378C. This short “prelabeling” of antigen-specific
CTL prior to activation has been used to overcome the problem ofcells where it is loaded with a variety of endogenous
TCR downregulation after antigen stimulation (Appay et al., 2000).peptides. It would also be possible to produce soluble
The short incubation with tetramer did not induce CTL apoptosisforms of these molecules loaded with unknown host
above background levels (data not shown). After washing, cells were
peptides by expression in mammalian cells and conceiv- incubated for 8 hr at 378C in the 96-well round-bottom plates with
ably in cells derived from the patient for whom therapy targets. The B cell targets were pulsed and washed (to remove free
was planned. Our further experiments will test the utility peptide) with index CMV matrix peptide (NLVPMVATV) or irrelevant
peptide at different PBMC:target ratios (200:1, 100:1, and 50:1).of these approaches in the treatment of CD8-mediated
Different concentrations (1/1000, 1/500, and none) of blocking anti-autoimmunity models and organ transplantation.
CD8 antibody (MF8 ascites) were added to the cultures. At the end
of the assay, cells were washed and stained with anti-CD3-Tricolor
Experimental Procedures and Annexin V-FITC (*1828-681; Boehringer Mannheim).
CTL Clones and Target Cells
Three HLA-A2-restricted and one HLA-B8-restricted CD81 CTL Apoptosis Assays
CTLs were incubated with target cells at different E:T ratios asclones were used in this study; the 868 clone specific for HIV-1 gag
epitope (SLYNTVATL), two influenza-specific clones (9C and Nikila) indicated or with the multimeric beads (five beads per cell or as
indicated) in 96-well flat-bottom plates in a final volume of 200 mlfor matrix protein 58-66 (GILGFVFTL), and the LC13 clone specific
for the EBV epitope FLR and alloreactive to HLA-B4402 have been for the time indicated. The cells were then harvested for apoptosis
assays. For inhibition of apoptosis, reagents were added at thedescribed previously (Burrows et al., 1999; Dunbar et al., 1998; Tan
et al., 1999). Targets used in this study were EBV-transformed B beginning of the assay, at a final concentration of rIL-2 (20 U/ml),
anti-FasL mAb (5 mg/ml; kindly provided by Dr Nagata), anti-TNFcell lines (BCL), the T2 cell line (A21Tap2), and T2 or BCLs stably
transfected with human b2 microglobulin (b2M) fused to the Flu neutralizing mAb (50 mg/ml), Ig-fusion proteins (20 mg/ml), caspase-
inhibitors (z-VAD and the control z-FA-FK; 10 mM; Enzyme Systems),matrix peptide 58-66 (FluMP58-66) using a retroviral vector as de-
scribed previously (Tafuro et al., 2001). The .221 cell lines (MHC or a blocking anti-CD8 mAb (MF8). Three methods for detecting
apoptotic cells were used. (1) Annexin V staining or TUNEL assay:class I negative) stably expressing HLA-A2 wild-type (A2wt), B4402
wild-type (B4402wt), or their mutants (A2mt or B4402mt) were made CTLs were labeled with anti-CD8 (Tricolor; Caltag) and BCL targets
with anti-CD19 (PE; Dako) and then stained with Annexin V-FITC orby transfection with full-length cDNA clones fused to GFP in pEGFP-
N1 (Clontech, UK). Mutants of A2 and B4402 were generated by TUNEL (FITC) according to the manufacturer’s protocols. (2) JAM
assay: in brief, the CTLs were cultured with [3H]TdR (1 mCi/ml) forsubstitution of amino acids D and T at position 227 and 228 with K
and A (227K/228A) in the a3 domain on the basis of structure of 12 to 24 hr, washed three times, and then cultured with the
multimeric beads for another 12 hr. DNA fragmentation was deter-CD8 and HLA-2 interaction (Gao et al., 1997). The vectors were
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mined by [3H]thymidine release (Matzinger, 1991). (3) Finally, death Combadiere, B., e Sousa, C.R., Germain, R.N., and Lenardo, M.J.
(1998). Selective induction of apoptosis in mature T lymphocytesof target cells was also assessed by a standard 51Cr release assay.
Although the apoptosis of CTL and the target can be monitored by variant T cell receptor ligands. J. Exp. Med. 187, 349–355.
simultaneously by three-color flow cytometry, we found that Annexin Daniels, M.A., and Jameson, S.C. (2000). Critical role for CD8 in T cell
V staining was more reliable and sensitive for analysis of CTL apo- receptor binding and activation by peptide/major histocompatibility
ptosis because CTLs were not labeled well with 51Cr (they often complex multimers. J. Exp. Med. 191, 335–346.
show high spontaneous release). On the other hand, the 51Cr release
Dhein, J., Walczak, H., Baumler, C., Debatin, K.M., and Krammer,
assay was used to monitor apoptosis of target cells because most
P.H. (1995). Autocrine T-cell suicide mediated by APO-1/(Fas/CD95).
BCL including .221 gave a high background staining with Annexin
Nature 373, 438–441.
V (data not shown). In general, the 51Cr release assay is much quicker
Dunbar, P.R., Ogg, G.S., Chen, J., Rust, N., van der Bruggen, P.,(within 4 hr) and mainly measures for perforin release, whereas
and Cerundolo, V. (1998). Direct isolation, phenotyping and cloningAnnexin V staining is much slower (.4 hr) and mainly measures
of low-frequency antigen-specific cytotoxic T lymphocytes from pe-apoptosis induced by cell surface death molecules.
ripheral blood. Curr. Biol. 8, 413–416.
Fisher, G.H., Rosenberg, F.J., Straus, S.E., Dale, J.K., Middleton,TCR Signaling
L.A., Lin, A.Y., Strober, W., Lenardo, M.J., and Puck, J.M. (1995).FluMP58-66-specific CTLs (2 3 106) were incubated with multimeric
Dominant interfering Fas gene mutations impair apoptosis in a hu-beads (five beads per cell) for the time indicated at 378C. Cells were
man autoimmune lymphoproliferative syndrome. Cell 81, 935–946.then lysed as previously described (Purbhoo et al., 1998) and the
lysate cleared by centrifugation and resolved by SDS-PAGE. Follow- Gao, G.F., Tormo, J., Gerth, U.C., Wyer, J.R., McMichael, A.J., Stuart,
ing transfer, the Western blot was probed with the anti-phosphotyro- D.I., Bell, J.I., Jones, E.Y., and Jakobsen, B.K. (1997). Crystal struc-
sine mAb (4G10; Upstate Biotechnology) followed by a secondary ture of the complex between human CD8alpha(alpha) and HLA-A2.
antibody conjugated with HRP and revealed using enhanced chemi- Nature 387, 630–634.
luminescence (ECL). Equal loading of lanes was demonstrated by Gaur, A., Wiers, B., Liu, A., Rothbard, J., and Fathman, C.G. (1992).
reprobing the blot with a monoclonal antibody to total cellular ZAP- Amelioration of autoimmune encephalomyelitis by myelin basic pro-
70 (Santa Cruz) or b-actin (Sigma). tein synthetic peptide-induced anergy. Science 258, 1491–1494.
Kersh, E.N., Shaw, A.S., and Allen, P.M. (1998). Fidelity of T cell
Acknowledgments activation through multistep T cell receptor zeta phosphorylation.
Science 281, 572–575.
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